Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
Authors
Keywords
-
Journal
CNS DRUGS
Volume 36, Issue 2, Pages 191-202
Publisher
Springer Science and Business Media LLC
Online
2022-02-11
DOI
10.1007/s40263-021-00893-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
- (2021) Messoud Ashina et al. EUROPEAN JOURNAL OF NEUROLOGY
- Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study
- (2021) Stewart J. Tepper et al. JOURNAL OF HEADACHE AND PAIN
- Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study
- (2021) Marta Torres-Ferrús et al. JOURNAL OF NEUROLOGY
- Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
- (2021) Andrew M. Blumenfeld et al. Pain and Therapy
- Refractory migraine profile in CGRP‐monoclonal antibodies scenario
- (2021) Marcello Silvestro et al. ACTA NEUROLOGICA SCANDINAVICA
- Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
- (2021) Piero Barbanti et al. HEADACHE
- Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache
- (2021) Umberto Pensato et al. NEUROLOGICAL SCIENCES
- Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?
- (2021) Theodoros Mavridis et al. Pharmaceuticals
- Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
- (2020) Stewart J Tepper et al. CEPHALALGIA
- Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
- (2020) Bianca Raffaelli et al. Frontiers in Neurology
- Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
- (2020) Rami Burstein et al. HEADACHE
- Access to Migraine Treatments in Ontario, Canada: A Review of the Ontario Drug Benefit Program
- (2020) Susan Cape HEADACHE
- European headache federation consensus on the definition of resistant and refractory migraine
- (2020) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
- (2020) Antonio Russo et al. JOURNAL OF HEADACHE AND PAIN
- A prospective real-world analysis of erenumab in refractory chronic migraine
- (2020) Giorgio Lambru et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
- (2020) Armin Scheffler et al. JOURNAL OF HEADACHE AND PAIN
- Real-world effectiveness and tolerability of erenumab: A retrospective cohort study
- (2020) Saad Kanaan et al. CEPHALALGIA
- Erenumab in Chronic Migraine: An Australian Experience
- (2020) Shuli Cheng et al. HEADACHE
- Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine
- (2020) Jennifer Robblee et al. HEADACHE
- Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)
- (2020) Fabrizio Vernieri et al. NEUROLOGICAL SCIENCES
- One year experience with erenumab: real-life data in 30 consecutive patients
- (2020) Angelo Ranieri et al. NEUROLOGICAL SCIENCES
- Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center
- (2020) Eleonora Matteo et al. NEUROLOGICAL SCIENCES
- Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study
- (2020) Francesca Schiano di Cola et al. NEUROLOGICAL SCIENCES
- Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study
- (2020) Piero Barbanti et al. HEADACHE
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in chronic migraine with medication overuse
- (2019) Stewart J. Tepper et al. NEUROLOGY
- Blocking CGRP in migraine patients – a review of pros and cons
- (2017) Marie Deen et al. JOURNAL OF HEADACHE AND PAIN
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search